BD Steps Up Presence in Stem Cell Research Market
According to Fate Therapeutics’ website, the company’s technology induces pluripotency by using proteins, instead of genetic modification, which is safer and more efficient. Fate Therapeutics CFO Scott Wolchko told The Scientist in 2009 that research applications of the technology could include toxicology testing and development of lower-priced reagents. Fate Therapeutics is using the technology to develop therapeutic stem cell modulators.
San Diego, CA and Ottawa, Canada 10/14/10—Fate Therapeutics announced that it has signed a three-year collaboration and licensing agreement with BD Biosciences for the development and commercialization of induced pluripotent stem cell technologies for drug discovery and development. The companies will jointly develop products that BD Biosciences will commercialize. The agreement includes exclusive licenses to the work of Rudolf Jaenisch, MD, and Sheng Ding, PhD. Fate Therapeutics will receive an up-front payment, research funding, commercialization milestones and royalties. Financial details were not disclosed.

